Please provide your email address to receive an email when new articles are posted on . Nearly half of men with metastatic castration-resistant prostate cancer eligible for PARP inhibitors do not get ...

Among patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations, nearly half (48.8%) did not receive a PARP inhibitor, despite recent FDA approvals and recent trials ...

CHICAGO -- Men with homologous recombination repair (HRR)-deficient, metastatic, castration-sensitive prostate cancer (mCSPC) lived significantly longer without disease progression when they received ...

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led ...

Johnson & Johnson (NYSE:JNJ) said on Tuesday that niraparib, a cancer treatment from a group of drugs called PARP inhibitors, successfully met its main goal in a Phase 3 trial for prostate cancer when ...

In a statement, NICE said the new guidance for Talzenna will make it an option for around 2,400 people in England and reduce ...

Please provide your email address to receive an email when new articles are posted on . Adding niraparib to abiraterone acetate and prednisone lowered risk for cancer growth by 37% among certain ...

NICE now recommends NHS use of the daily pill to patients with metastatic prostate cancer.

With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent cancer and the fifth leading cause of cancer death among men in 2022. Hormone ...